$160 Million is the total value of Prosight Management, LP's 46 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 67.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Sell | PROTHENA CORP PLC | $21,695,000 | +43.9% | 422,000 | -29.7% | 13.57% | +9.9% |
| ALBO | Buy | ALBIREO PHARMA INC | $10,381,000 | +72.9% | 295,080 | +73.2% | 6.49% | +32.0% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $9,343,000 | +27.2% | 137,000 | +29.5% | 5.84% | -2.8% |
| HAE | New | HAEMONETICS CORP MASS | $8,930,000 | – | 134,000 | +100.0% | 5.58% | – |
| CUE | Buy | CUE BIOPHARMA INC | $7,344,000 | +8.1% | 630,364 | +13.2% | 4.59% | -17.4% |
| EHC | Sell | ENCOMPASS HEALTH CORP | $6,867,000 | -16.2% | 88,000 | -12.0% | 4.29% | -36.0% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $6,744,000 | +19.9% | 595,239 | +25.7% | 4.22% | -8.4% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $5,559,000 | +24.3% | 1,023,704 | +36.4% | 3.48% | -5.1% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $5,464,000 | -33.7% | 27,100 | -29.3% | 3.42% | -49.4% |
| XCUR | Buy | EXICURE INC | $5,400,000 | +798.5% | 3,600,000 | +1205.1% | 3.38% | +586.4% |
| ZGNX | Buy | ZOGENIX INC | $5,284,000 | +38.8% | 305,788 | +56.8% | 3.30% | +6.0% |
| ZBH | Buy | ZIMMER BIOMET HOLDINGS INC | $5,066,000 | +49.3% | 31,500 | +48.6% | 3.17% | +14.0% |
| GLPG | Buy | GALAPAGOS NVspon adr | $4,960,000 | -3.1% | 72,000 | +8.4% | 3.10% | -26.0% |
| CNVY | New | CONVEY HLDG PARENT INC | $4,670,000 | – | 410,412 | +100.0% | 2.92% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $4,341,000 | – | 181,171 | +100.0% | 2.71% | – |
| MGTX | Sell | MEIRAGTX HLDGS PLC | $4,240,000 | +0.6% | 273,523 | -6.3% | 2.65% | -23.2% |
| RCM | New | R1 RCM INC | $3,821,000 | – | 171,817 | +100.0% | 2.39% | – |
| MORF | Buy | MORPHIC HLDG INC | $3,690,000 | +1021.6% | 64,292 | +1135.9% | 2.31% | +757.6% |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $3,614,000 | – | 138,886 | +100.0% | 2.26% | – |
| MTCR | Buy | METACRINE INC | $3,303,000 | +74.9% | 869,082 | +185.4% | 2.06% | +33.6% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $2,831,000 | -4.9% | 420,000 | -6.7% | 1.77% | -27.4% |
| QSI | New | QUANTUM SI INC | $2,788,000 | – | 227,391 | +100.0% | 1.74% | – |
| UNH | Sell | UNITEDHEALTH GROUP INC | $2,002,000 | -10.3% | 5,000 | -16.7% | 1.25% | -31.5% |
| LHCG | Buy | LHC GROUP INC | $1,980,000 | +17.9% | 9,888 | +12.6% | 1.24% | -10.0% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $1,685,000 | -64.0% | 130,000 | -64.0% | 1.05% | -72.5% |
| ATIP | New | ATI PHYSICAL THERAPY INC | $1,653,000 | – | 173,276 | +100.0% | 1.03% | – |
| MDT | Sell | MEDTRONIC PLC | $1,365,000 | -42.5% | 11,000 | -45.2% | 0.85% | -56.0% |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $1,340,000 | – | 20,200 | +100.0% | 0.84% | – |
| CLLS | Sell | CELLECTIS S Aspon ads | $1,331,000 | -52.2% | 86,036 | -37.6% | 0.83% | -63.5% |
| OSCR | Sell | OSCAR HEALTH INCcl a | $1,182,000 | -58.9% | 55,000 | -48.6% | 0.74% | -68.6% |
| New | ALBIREO PHARMA INCcall | $1,157,000 | – | 32,900 | +100.0% | 0.72% | – | |
| EVH | New | EVOLENT HEALTH INCcl a | $1,099,000 | – | 52,023 | +100.0% | 0.69% | – |
| CLOV | New | CLOVER HEALTH INVESTMENTS CO | $1,054,000 | – | 79,100 | +100.0% | 0.66% | – |
| Sell | AKUMIN INC | $1,032,000 | -35.0% | 327,680 | -23.6% | 0.64% | -50.4% | |
| New | AURINIA PHARMACEUTICALS INCcall | $871,000 | – | 67,200 | +100.0% | 0.54% | – | |
| NUVB | New | NUVATION BIO INC | $854,000 | – | 91,694 | +100.0% | 0.53% | – |
| SIOX | Buy | SIO GENE THERAPIES INC | $699,000 | +30.2% | 256,115 | +24.4% | 0.44% | -0.7% |
| ONCR | Sell | ONCORUS INC | $690,000 | -30.0% | 50,000 | -29.4% | 0.43% | -46.6% |
| OPCH | New | OPTION CARE HEALTH INC | $610,000 | – | 27,875 | +100.0% | 0.38% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $578,000 | +122.3% | 149,090 | +163.9% | 0.36% | +69.5% |
| XFOR | New | X4 PHARMACEUTICALS INC | $571,000 | – | 87,813 | +100.0% | 0.36% | – |
| RPHM | New | RENEO PHARMACEUTICALS INC | $513,000 | – | 54,934 | +100.0% | 0.32% | – |
| Sell | APTOSE BIOSCIENCES INC | $442,000 | -50.7% | 133,000 | -11.3% | 0.28% | -62.4% | |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $417,000 | +50.0% | 25,100 | +64.8% | 0.26% | +14.5% |
| CANO | New | CANO HEALTH INC | $281,000 | – | 23,200 | +100.0% | 0.18% | – |
| ADMA | Sell | ADMA BIOLOGICS INC | $184,000 | -79.0% | 115,100 | -76.9% | 0.12% | -84.0% |
| ODT | Exit | ODONATE THERAPEUTICS INC | $0 | – | -117,621 | -100.0% | -0.33% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -5,800 | -100.0% | -0.40% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -8,685 | -100.0% | -1.09% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -17,000 | -100.0% | -1.11% | – |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -320,100 | -100.0% | -1.45% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -1.78% | – |
| INOV | Exit | INOVALON HLDGS INC | $0 | – | -85,000 | -100.0% | -2.00% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -95,600 | -100.0% | -4.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.